colorectal cancer
Conditions
Interventions
Patient1:Received 1 x 10^7 / m^2 NRC-NK cells infusion on day 0, followed by a second 6 x 10^7 / m^2 NRC-NK cells infusion on day 7 and a third 3 x 10^8 / m^2 NRC -NK cells infusion on day 14
Patient1:6 x10^7/m2 NRC-NK cells,twice a week and 3 x10^8/m2 NRC-NK cells, twice a week, with one week between the two doses
Patient2:Accept 3 x 10 ^ 8 / m ^ 2 CAR-NK cell input twice a week for 3 weeks
Patient3:Accept 3 x 10 ^ 8 / m ^ 2 CAR-NK cell input twice a week for 3 weeks
Sponsors
the Third Affiliated Hospital, Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
17 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old; 2. Histological or cytologically confirmed peritoneal metastasis of colorectal cancer, malignant ascites; 3. Expected life is greater than 90 days; 4. ECOG physical status score 0-1 or KPS score = 60 points; 5. Heart, liver and kidney function within the normal range or controllable range (heart function does not exceed 2, ALT and / or AST does not exceed the normal upper limit of 1.5 times, Cr does not exceed the normal upper limit); 6. With a single or intravenous blood intake sufficient venous access, and no other blood separation contraindications; 7. By MDT discussion without a definite basis to benefit from surgery; 8. Treatment by MDT No benefit from chemotherapy therapy (FOLFOX / FOFIRI regimen has been completed, or incomplete patient can not tolerate / reject further chemotherapy), chemotherapy has stopped 4 weeks before patient receiving NRC-NK cell immunotherapy; 9. Volunteer to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. With acute or chronic infections associated with blood diseases, cardiovascular disease, lung disease, liver disease, kidney disease, pancreatic disease, endocrine disease; 2. Immune deficiency, autoimmune diseases; 3. Have severe allergies; 4. Received cell therapy in the previous 3 months; 5. Received systemic steroid therapy; 6. Pregnant or lactating women; 7. Brain metastases; 8. After being informed of the program, do not want to enter the group or not in line with the medical ethics committee on the project resolution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood routine;Urine routine;Liver and kidney function;Electrocardiogram;weight;Physical status score;Ultra sound examination of ascites;CT;MRI;Survival period;Ultra sound examination of liver and gallbladder;Circulating tumor cells;Analysis of serum CEA levels;Blood cell phenotype analysis;Plasma cytokine detection;Ascites cell phenotype analysis;Ascites cytokine detection; | — |
Countries
China
Contacts
Public ContactXu Xuehu
the Third Affiliated Hospital, Guangzhou Medical University
Outcome results
None listed